Regenerative medical devices company Tissue Regenix said its dCELL woundcare product DermaPure has now surpassed the $1m sales mark, following its commercialisation in the US.
The product is primarily aimed at the treatment of chronic wounds associated with diabetes. Approximately 10 per cent of the American population is currently suffering from Type one or Type two diabetes, making the prevalence of hard to heal wounds, a common side effect of the disease, increase rapidly.
DermaPure has been proved to be successful in treating big, long term wounds. The group’s decellularisation process removes DNA and other cellular material from animal and human tissue leaving a tissue scaffold which is not rejected by the patient’s body.
Greg Bila, president of Tissue Regenix Woundcare, said: “Since launch in 2014, the uptake of DermaPure within a competitive marketplace has been highly encouraging and we are thrilled to announce the first $1m of sales. We are finding that it is the intrinsic qualities of DermaPure which make it effective and differentiate it from other products available.”
Last year the York-based group reported substantial commercial interest in DermaPure and signed a deal with US health insurance firm CGS Medicare covering the states of Ohio and Kentucky, adding a further 1.9 million Medicare beneficiaries.
Yesterday the firm appointed Jonathan Glenn as a non-executive director. Mr Glenn has been chief executive at Consort Medical plc since December 2007, having originally joined the company in September 2006 as chief financial officer. Prior to joining Consort Medical, he held a number of senior financial roles across the medical industry